Welcome to our dedicated page for Metsera news (Ticker: MTSR), a resource for investors and traders seeking the latest updates and insights on Metsera stock.
Metsera, Inc. (formerly NASDAQ: MTSR) generates a distinctive news profile at the intersection of biotechnology, obesity therapeutics, and large-cap pharmaceutical dealmaking. As a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, Metsera has issued frequent updates on its pipeline programs, particularly MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing. News coverage has highlighted Phase 2b results from the VESPER-1 and VESPER-3 trials, including dose-dependent weight loss and detailed gastrointestinal tolerability data in participants with overweight or obesity without type 2 diabetes.
Another major theme in MTSR news has been strategic transactions. Filings and press releases describe Metsera’s entry into an Agreement and Plan of Merger with Pfizer, subsequent amendment of the merger terms, and competing unsolicited proposals from Novo Nordisk A/S that were deemed “Superior Company Proposals” by Metsera’s Board. News items track the evolution of these offers, changes to cash consideration and contingent value rights (CVRs), and related litigation between Metsera and Pfizer over deal terms and regulatory considerations.
For readers following MTSR-related developments, this news stream includes: clinical trial milestones for MET-097i and its combination, oral, and prodrug programs; regulatory and antitrust steps such as early termination of the Hart-Scott-Rodino waiting period; Board determinations regarding competing bids; and the ultimate completion of Pfizer’s acquisition of Metsera and the resulting delisting of MTSR from the Nasdaq Global Select Market. Investors, analysts, and healthcare observers can use this page to review how Metsera’s scientific progress and transaction process unfolded over time.
Pfizer (NYSE: PFE) completed its acquisition of Metsera on November 13, 2025, buying all outstanding Metsera shares for $65.60 per share in cash and an enterprise value of approximately $7.0 billion.
The deal includes a contingent value right (CVR) of up to $20.65 per share tied to three clinical and regulatory milestones. Metsera is now a Pfizer subsidiary and its common stock will cease trading on NASDAQ. Key assets transferred include MET-097i (weekly/monthly GLP-1 RA entering Phase 3), MET-233i (monthly amylin analog in Phase 1), an oral GLP-1 RA in Phase 1, and preclinical hormone therapeutics.
Pfizer expects the transaction to be dilutive through 2030 and will update financial outlook with 2026 guidance later this year.
Metsera (NASDAQ: MTSR) entered an amended merger agreement with Pfizer on Nov 7, 2025, valuing Metsera at up to $86.25 per share—comprised of $65.60 cash plus a contingent value right (CVR) of up to $20.65.
Metsera's board unanimously recommends shareholders approve the amended agreement and expects to close promptly after the special stockholder meeting on November 13, 2025. The board cited antitrust concerns related to an alternate Novo Nordisk proposal and reaffirmed that the Pfizer transaction offers immediate, certain value.
Metsera (NASDAQ: MTSR) issued a statement on Nov 5, 2025 after the Delaware Court of Chancery denied Pfizer's request for a temporary restraining order to block Metsera's board from acting on behalf of shareholders. Metsera characterized Pfizer's litigation as baseless and said its board will continue to act for shareholders and patients.
The release warns the proposed Pfizer acquisition remains subject to litigation risks, potential regulatory approvals, shareholder votes, transaction costs, and the possibility the deal may not close. Investors are directed to Metsera's proxy materials and SEC filings for further information.
Metsera (NASDAQ: B) announced its board has declared an amended acquisition proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal values Metsera at up to $86.20 per share (~$10.0B), including an immediate cash payment/dividend of $62.20 per share and a second-step contingent value right (CVR) of up to $24.00 per share. Metsera notified Pfizer, triggering a two-business-day negotiation period under the Pfizer Merger Agreement.
Metsera (NASDAQ: B) announced that its board has declared an amended proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer on Nov 4, 2025. The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share (~$10.0 billion) via a two-step structure: an immediate $62.20 per share cash payment plus non-voting preferred stock, followed by a dividend of $62.20, and a contingent value right (CVR) worth up to $24.00 per share upon regulatory and development milestones.
Metsera notified Pfizer, triggering a two-business-day period for Pfizer to propose adjustments under the Pfizer Merger Agreement; Pfizer previously revised its proposal to $60.00 upfront + up to $10.00 CVR.
Metsera (NASDAQ: MTSR) issued a statement on Nov 13, 2025 responding to litigation filed by Pfizer over Pfizer's proposed acquisition of Metsera. Metsera said Pfizer's litigation seeks to reduce Pfizer's purchase price compared with an unsolicited proposal from Novo Nordisk and that Metsera's board will defend shareholder interests in court.
The release reiterates forward-looking risks tied to the proposed acquisition, including litigation costs, possible damages, the potential that the transaction may not close, regulatory approvals, stockholder votes, and other business and clinical risks. Metsera noted it has filed proxy materials with the SEC and that the definitive proxy has been mailed to stockholders.
Metsera (NASDAQ: MTSR) issued a statement on October 31, 2025 responding to litigation filed by Pfizer, saying Metsera disagrees with the allegations and will address them in the Delaware Court of Chancery.
The release notes risks tied to Pfizer's proposed acquisition of Metsera, including litigation costs, potential damages, possible effects on the timing or completion of the transaction, impacts on Metsera stock price, and references an unsolicited proposal from Novo Nordisk. Metsera also confirms that its definitive proxy statement has been mailed to stockholders and directs investors to SEC filings for more information.
Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.
Metsera (NASDAQ: B) announced its board has declared an unsolicited proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal would pay $56.50 per share in cash at signing, issue Novo non-voting preferred stock representing 50% of Metsera's share capital, then pay a CVR up to $21.25 per share upon milestones, valuing Metsera at up to $77.75 per share (~$9 billion).
The proposal represents an approximate 133% premium to Metsera's close on Sept 19, 2025. Metsera notified Pfizer, triggering a four-business-day period for Pfizer to propose adjustments; Pfizer disputes Metsera's right to deliver the notice. The Pfizer merger agreement remains in effect and Metsera's board reaffirmed its recommendation to approve the Pfizer transaction; no shareholder action is required now.
Summary not available.
FAQ
What is the current stock price of Metsera (MTSR)?
What is the market cap of Metsera (MTSR)?
